ulocuplumab   Click here for help

GtoPdb Ligand ID: 9161

Synonyms: BMS-936564 | MDX-1338
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ulocuplumab is an IgG4 kappa anti-CXCR4 monoclonal, being developed by Bristol-Myers Squibb as a potential oncolgy therapeutic.
Peptide sequences and structural details for this antibody are available from its IMGT/mAb-DB record.
BLAST sequence analysis of the heavy and light chain peptide sequences of ulocuplumab, reveal identical matches with sequences claimed in patent US8450464 [5]. This identifies clone F7GL as the likely candidate for ulocuplumab.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos JC. (2000)
Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease.
J Immunol, 165 (1): 499-508. [PMID:10861089]
2. Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y et al.. (2005)
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.
Cancer Res, 65 (13): 5864-71. [PMID:15994964]
3. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Murakami K, Miyake Y, Matsuo T. (2005)
CXCL12 and CXCR4 expression by human gingival fibroblasts in periodontal disease.
Clin Exp Immunol, 141 (3): 467-74. [PMID:16045736]
4. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B et al.. (2006)
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.
Nat Med, 12 (5): 557-67. [PMID:16648859]
5. Kuhne M, Brams P,Tanamachi DM,Korman AJ, Cardarelli JM. (2013)
Human monoclonal antibodies that bind CXCR4.
Patent number: US8450464 B2. Assignee: Medarex, Inc.. Priority date: 02/10/2006. Publication date: 28/05/2013.
6. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, De Clercq E, Billiau A, Schols D. (2001)
AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.
J Immunol, 167 (8): 4686-92. [PMID:11591799]
7. Terada R, Yamamoto K, Hakoda T, Shimada N, Okano N, Baba N, Ninomiya Y, Gershwin ME, Shiratori Y. (2003)
Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases.
Lab Invest, 83 (5): 665-72. [PMID:12746476]